Arcoma AB (OSTO:ARCOMA) Current Deferred Revenue: kr0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ARCOMA Arcoma AB OSTO:ARCOMA
74 GF Score
Price kr8.58
GF Value kr7.91
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Arcoma AB Current Deferred Revenue?

Arcoma AB OSTO:ARCOMA 74 Current Deferred Revenue is kr0.0 Mil as of Mar. 2026. GuruFocus rates OSTO:ARCOMA with a GF Score™ of 74/100 and a GF Value™ of kr7.91 (Fairly Valued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Arcoma AB's current deferred revenue for the quarter that ended in Mar. 2026 was kr0.0 Mil.

Arcoma AB Current Deferred Revenue Related Terms

Arcoma AB Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Arcoma AB's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcoma AB Current Deferred Revenue Chart

Arcoma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Arcoma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ARCOMA
74GF Score
Arcoma AB OSTO:ARCOMA
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of kr0.0 Mil mean?
Arcoma AB (OSTO:ARCOMA) has a Current Deferred Revenue of kr0.0 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Arcoma AB and its competitors.
Is Arcoma AB's Current Deferred Revenue too high?
Arcoma AB's current Current Deferred Revenue is kr0.0 Mil. Overall, Arcoma AB has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Arcoma AB's Current Deferred Revenue compare to ABT and SYK?
Arcoma AB's Current Deferred Revenue of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Arcoma AB and its competitors. Arcoma AB's current Current Deferred Revenue is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcoma AB stock overvalued right now?
Based on GuruFocus' analysis, Arcoma AB (OSTO:ARCOMA) is currently considered Fairly Valued. The stock's GF Value™ is kr7.91, compared to a current price of kr8.58 — trading 8.5% above its estimated fair value. The current Current Deferred Revenue is kr0.0 Mil. Arcoma AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Arcoma AB (OSTO:ARCOMA), the current Current Deferred Revenue is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcoma AB (OSTO:ARCOMA) Overvalued in 2026?

Based on GuruFocus' analysis, Arcoma AB stock appears to be overvalued. The current stock price of kr8.58 is trading 8.5% above its estimated GF Value™ of kr7.91. GuruFocus considers Arcoma AB to be Fairly Valued.

Key valuation signals for OSTO:ARCOMA:

  • Current Deferred Revenue: kr0.0 Mil
  • GF Value™: kr7.91 vs. price of kr8.58 (8.5% above fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the OSTO:ARCOMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcoma AB Business Description

Address Annavagen 1, Vaxjo, SWE, SE-352 46
Arcoma AB provides digital radiography systems in Sweden. It offers products including wireless flat panel detectors, positioning devices, and precision dr systems.
74GF Score

Get the complete analysis for OSTO:ARCOMA

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr8.58
Price
kr7.91
GF Value